Review Article

What are the likely causes of breast implant associated anaplastic large cell lymphoma (BIA-ALCL)?

Sepehr S. Lajevardi, Pratik Rastogi, Daniel Isacson, Anand K. Deva*

Department of Plastic, Reconstructive & Maxillofacial Surgery – Macquarie University, NSW, Australia

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma. Where implant history is known, all confirmed cases to date have occurred in patients with exposure to textured implants. The etiopathogenesis of BIA-ALCL is likely to be multifactorial, with current evidence-based theories recognising the combination of chronic infection in setting of textured implants, gram-negative biofilm formation, chronic inflammation, host genetics (e.g. JAK/STAT, p53) and time in tumorigenesis. Proposed triggers for the development of malignancy are mechanical friction, silicone implant shell particulates, silicone leachables and bacteria. Of these, the bacterial hypothesis has received significant attention, supported by a plausible biological model. In this model, bacteria form an adherent biofilm in the favourable environment of the textured implant surface, producing a bacterial load that elicits a chronic inflammatory response. Bacterial antigens, primarily of gram-negative origin, may trigger innate immunity and induce T-cell proliferation with subsequent malignant transformation in genetically susceptible individuals. Future research, investigating BIA-ALCL genetic mutations and immunological modulation with...
Gram-negative biofilm in BIA-ALCL models is warranted to establish a unifying theory for the aetiology of BIA-ALCL. © 2022 The Author(s). Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently recognised and distinct malignancy of T lymphocytes exclusively associated with textured breast implants used for both aesthetic and reconstructive surgery.1 There is a spectrum of disease presentation, with the most commonly occurring as a seroma with an indolent course. A less common presentation occurs as locally advanced mass disease or rarely as metastatic disease. The pathognomonic histological response to breast implant insertion is benign capsule formation. Smooth surface implants are associated with higher rates of benign capsular contracture,2,3 because they predispose to a planar arrangement of fibroblasts with organised collagen deposition around implants. By contrast, textured implants typically have grooves larger than the diameter of a fibroblast,4,5 disrupting the planar arrangement of cells and reducing the risk of capsular contracture. Surface texturing on the external silicone shell of breast implants may involve salt loss, gas diffusion, imprinting and other recent proprietary “nano” texturing techniques.6,7

The exact pathogenic mechanisms surrounding BIA-ALCL are unclear. Prevailing theories recognise the role of the breast microbiome and textured implants, which potentially trigger malignant transformation in the milieu of sustained antigen-driven inflammation. Despite the reduction of capsular contracture rates with implant texturisation2,2 their greater surface area and rough interface enhances bacterial adhesion and biofilm burden.8,9

Anaplastic large cell lymphoma

Primary breast lymphomas are rare, accounting for 0.04%–0.5% of all breast cancers.10,11 The vast majority of these lymphomas are derived from B-lymphocytes and less than 10% are of T-cell origin.10-12 Anaplastic Large Cell Lymphoma (ALCL) is a subset of T-cell lymphoma that includes systemic, primary cutaneous and breast implant-associated subtypes. Systemic ALCL is further subcategorised according to the expression or absence of the anaplastic lymphoma kinase (ALK) protein; ALK-positive disease is most commonly the result of 2p23/ALK aberrations, including the classic t(2;5)(p23;q35)/NPM1-ALK translocation. Systemic ALCL with negative ALK expression confers a poor prognosis with a reported 5-year estimated survival of 40%–60%.13 Cutaneous ALCL falls with the group of so-called primary cutaneous CD30-positive lymphoproliferative diseases that include the very indolent condition of lymphomatoid papulosis which manifests as spontaneous waxing and waning skin papules that self-resolve, to the potentially more aggressive primary cutaneous ALCL. Importantly, and unlike its systemic counterpart, primary cutaneous ALCL is typically ALK-negative yet has a comparably very favourable 10-year survival rate of 90%.14 BIA-ALCL is a CD30+, ALK-negative lymphoma with a typically indolent progression.15 In summary, although the spectrum of ALCL has a similar histological appearance, their clinical behaviour across the various types varies widely.

Immunology

A cogent synthesis of BIA-ALCL pathobiology warrants a brief overview of the relevant T cell immunology.
T-cell development and activation

The T lymphocyte coordinates the adaptive immune response and together with the B lymphocyte, is responsible for generating immunologic memory against pathogens. T-cell programming is controlled by the T-cell receptor (TCR), which is generated by recombination of genomic DNA sequences in the thymus.\(^\text{16}\) Thymic progenitors rearrange the TCR genes in a temporal and location-specific manner.\(^\text{17}\) These naïve cells migrate from the thymus to secondary lymphoid tissues (e.g. spleen, lymph nodes) and are then activated by the coordinated interactions between an antigen-presenting cell, which binds an antigen to a major histocompatibility (MHC) class I or II molecule.\(^\text{16}\) The TCR (composed of two chains, \(\alpha\) and \(\beta\)) associates with a complex of membrane glycoproteins proteins, the cluster differentiation (CD) family, to stabilise the antigen and MHC complex into an immunological synapse. Other co-stimulatory signals are required for complete T-cell activation.\(^\text{16}\)

T-cell differentiation

The initial differentiation from a naïve T cell either into a T helper (CD4+) or T cytotoxic (CD8+). Once activated, the CD4+ cells can further differentiate into a number of subsets including Th1 (intracellular viral and bacterial pathogens), Th2 (large extracellular pathogens and allergic response), Th9 (parasitic infections), Th17 (mucosal immunity and autoimmune disorders), Th22 (inflammatory skin disorders), T\(_{\text{FH}}\) (follicular helper T cells regulate B cell activity) and Treg (inhibit pro-inflammatory T cells).\(^\text{16}\) Although T-cell lymphomas have been associated with viral infection such as EBV infection (Nasal NK lymphoma, Hydroavaccineforme-like lymphoma) and HTLV-I (Adult T-cell lymphoma/leukaemia), no viral elements (i.e. EBER) have been found in BIA-ALCL to date.

Pathogenesis

The prevailing hypothesis for BIA-ALCL formation unifies biofilm, implant texturing, chronic inflammation, and genetics in tumourigenesis (Fig. 1). Chronic antigenic stimulation is a key initiator and driver of lymphogenesis.\(^\text{18}\)

Chronic inflammation

Although the exact pathogenesis of BIA-ALCL has not been delineated, chronic inflammation has been hypothesised as a precursor to tumourigenesis. A sustained antigenic stimulus promotes a chronic inflammatory milieu, associated with the induction of reactive oxygen and nitrogen species, microRNA instability and epigenetic changes, promoting genetic instability\(^\text{19}\) (Fig. 1). There is evidence that cutaneous T-cell lymphomas are preceded by chronic inflammation.\(^\text{20}\) Similarly, the biological peptide, gluten, in combination with the intestinal microbiome, has been shown to drive T-cell receptor changes in patients with coeliac disease towards T-cell lymphoma transformation.\(^\text{21,22}\)

Supporting the chronic inflammation hypothesis, Lechner et al.\(^\text{23}\) detected high production of T-cell-associated cytokines IL-6 and IL-10 in their BIA-ALCL model. Autocrine IL-6 production has also been identified as a driver of tumourigenesis in some diffuse large B-cell lymphomas, as well as solid tumours including breast, lung and ovarian carcinomas.\(^\text{24,25}\) Moreover, Kadin et al.\(^\text{26}\) confirmed a Th17/Th1 phenotype of BIA-ALCL tumour lymphocytes, supporting the potential role of antigenic stimulation and chronic inflammation. Furthermore, Wolfram et al.\(^\text{27}\) showed intracapsular T cells producing IL-17, IFN-\(\gamma\), IL-6, IL-8 and TGF-\(\beta\), suggesting a Th17/Th1 weighted local immune response in silicone implants with capsular fibrosis. Nonetheless, it is clear that more research is required to evaluate the cytokine milieu and cellular phenotype of this condition.

Biofilm, implant texturing and the ALCI microbiome

The observation of chronic inflammation and the Th17/Th1 phenotype of BIA-ALCL lymphocytes supports the potential association between bacterial biofilms and tumourigenesis.\(^\text{17}\) Other potential
drivers of chronic inflammation include silicone particles,\textsuperscript{27,28} friction\textsuperscript{29} and heavy metals.\textsuperscript{30} With regard to silicone, there is no data to show that silicone particles or implant surfaces alone can initiate an immune response, sufficient to drive a T cell to malignancy.\textsuperscript{31} Regarding biofilms specifically, microbial adhesion to implant surfaces is facilitated by mechanical factors (pili/flagellae) and bacterial secretion of extra-cellular polysaccharide (EPS) matrix. Following attachment, bacterial proliferation and EPS matrix synthesis occurs, resulting in the formation of highly structured microcolonies.\textsuperscript{3,9,32} Dispersion of biofilm cells through active or passive detachment may contribute to local extension over the implant surface. The biofilm architecture contributes to host-resistance and survival advantages.\textsuperscript{3,9,20,32} The recruitment of macrophages and myofibroblasts, within the chronic inflammatory milieu, contributes to fibrous capsule formation around the implant.\textsuperscript{33}

A hypothesis involving the role of bacteria in the aetiology of BIA-ALCL has been proposed\textsuperscript{34,35} (Fig. 2). In this model, colonisation by bacteria of textured implants having a high surface area produces a biofilm, which, when the bacterial load exceeds a certain threshold value, leads to chronic antigen stimulation in genetically susceptible individuals. Eventually transformation occurs, leading to the emergence and proliferation of monoclonal CD30-positive ALK-negative T cells and the development of BIA-ALCL. Dysregulation of the JAK1/STAT3 pathway in affected cells is likely involved, and
the observed process is a slow one, typically requiring 8–12 years between implantation and BIA-ALCL diagnosis.\textsuperscript{34,33} All reported cases of BIA-ALCL have exclusively occurred in textured implants.\textsuperscript{36} Despite the benefits of tissue incorporation with texturisation, several in vitro studies have reported higher rates of biofilm formation in textured implants compared to smooth implants.\textsuperscript{4,37-39} This is attributed to their greater surface area and the enhanced bacterial adhesion on rough surfaces. Hu et al.\textsuperscript{8} reported that contamination of textured implants supports 30 times more biofilm bacteria than contaminated smooth implants. The authors also showed a linear correlation between the bacterial load in implant capsules and the number of activated lymphocytes and bacterial burden. The correlation was strongest for CD4+ T cells, the same phenotype as BIA-ALCL tumour cells.\textsuperscript{8}

Despite the antigenic stimulus and incumbent T cell proliferation, not all implant-associated biofilms and their capsules develop a malignant progeny (Fig. 1). In a study evaluating the microbiome of BIA-ALCL and non-tumour capsule samples, Hu et al.\textsuperscript{9} reported a gram-negative shift in ALCL specimens, with significantly greater proportions of \textit{Ralstonia} spp. observed. \textit{Ralstonia} spp., which are non-fermenting gram-negative bacilli found in soil and water, have been reported in nosocomial infections resulting from contamination of medical solutions.\textsuperscript{9,40} Contrastingly, \textit{Staphylococcus epidermidis}, a normal constituent of skin and endogenous breast microflora, is the most frequently identified organism on benign breast capsules.\textsuperscript{41-45} Reflecting these contrasting microbiomes, Hu et al.\textsuperscript{9} hypothesised two pathways of inflammation associated with breast implants: i) Gram-positive biofilm favouring fibrosis and capsular contracture formation and ii) Gram-negative biofilm favouring potential T-cell oncogene activation and malignant transformation (BIA-ALCL).

\textbf{Helicobacter pylori: an exemplum of microbiome induced malignancy}

The association between \textit{Ralstonia} spp. and BIA-ALCL parallels the link between \textit{H. pylori} and lymphomas of gastric mucosa-associated lymphoid tissue (MALT). Like the \textit{Ralstonia} spp., \textit{H. pylori} is also a non-fermenting gram-negative bacillus.\textsuperscript{40} Chronic inflammation induced by \textit{H. pylori}, which is mediated by direct activation of T cells, drives B cell mutations in MALT tissue leading to the emergence of a neoplastic B cell clone.\textsuperscript{8,46} \textit{H. pylori} virulence factors such as cytotoxin-associated gene A protein deregulate intra-cellular signalling pathways, promoting tumourigenesis.\textsuperscript{46,47} However, unlike...
BIA-ALCL lymphoma arising from *H. pylori* infection is of B-cell origin. This cellular difference possibly reflects the preferential activation of T-cell oncogenes in breast capsules in BIA-ALCL.

**Bacterial super-antigens and lipopolysaccharide**

Several hypotheses have recently been proposed to help explain the association between bacterial antigens and BIA-ALCL tumourigenesis (Fig. 1). The lipopolysaccharide coat of gram-negative bacteria, which is linked to other infectious and autoimmune diseases, has been proposed as a potential malignant trigger.\(^6^\) Bacterial superantigens may also play a role in tumourigenesis. Superantigens bind directly to the outer leaflet of the MHC Class II and the variable β chain (Vβ) of the T-cell receptor, causing direct activation and hyperstimulation of T cells of all subtypes.\(^4^9\) Unlike conventional antigens that activate less than 0.01% of T cells, superantigens activate around 20% of quiescent T cells causing a massive induction of cytokine release and T cell differentiation through a preferential Th1 pathway.\(^4^9\) Importantly, bacterial superantigens have been shown to be the only means to restrict the expansion of polyconal T cells in the Vβ region.\(^5^0\) Kadin et al.\(^3^1\) showed an expanded CD30+ TCRVβ T cell population in a case of BIA-ALCL, potentially implicating a role for a yet undefined, bacterial superantigen. No such antigen has been identified for *Ralstonia* spp. or related species to date.

Despite the associations, the observation of *Ralstonia* spp. in the microbiome does not prove causation of BIA-ALCL. Critics suggest that the *Ralstonia* spp. predominance in BIA-ALCL samples may represent an "opportunistic" infection drawn into the peri-tumoural region by chemotaxis or complex signal transduction.\(^5^2,5^3\) Research investigating host-bacteria interaction and virulence is warranted.

**Genetic mutations**

BIA-ALCL is likely a multifactorial disease of at-risk patients and a genetic predisposition for the development of BIA-ALCL continues to be explored.

There have been recent reports regarding the somatic genetic lesions (Fig. 1) associated with BIA-ALCL.\(^4,2^3,2^6,5^4-5^8\) Moreover, some have postulated that germline mutations may predispose to this condition.\(^5^4,5^9,6^0\) Future BIA-ALCL genomic studies, investigating potential germline and somatic tumour mutations would be beneficial.

**Janus kinase and signal transducer and activator of transcription (JAK-STAT)**

JAK-STAT pathway has been shown to mediate inflammation-associated cancers and been reported to have a key role in BIA-ALCL.\(^6^1\) The JAK-STAT pathway regulates embryonic development and signalling and is implicated in cell proliferation, differentiation and apoptosis.\(^5^4,5^6\) The pathway is deregulated across various types of T-cell lymphomas; however, the extent of deregulation is significantly higher in BIA-ALCL.\(^2^6,5^4,5^6,5^7\) present in 60% of cases according to a recent larger study.\(^5^1\)

The exact role of JAK/STAT signalling of oncogenesis in myoproliferative neoplasms is not understood. The mutations cause a hereditary thrombocytosis, but haematopoiesis is polyclonal and individuals do not develop haematological malignancies or solid tumours, suggesting that JAK/STAT activation alone does not drive malignant disease but are thought to promote survival of malignant cells.\(^5^2\) The consistent activation of the JAK-STAT3 pathway also suggests potential therapeutic options for BIA-ALCLs.

Several factors are likely to contribute to dysregulation of JAK-STAT. A loss of function SOCS1 mutation, causing constitutive activation of the JAK-STAT pathway, has been associated with BIA-ALCL.\(^5^6\) IL-2 and IL-6 overexpression has also been implicated in autocrine activation of JAK-STAT pathway in vitro studies.\(^2^3\) Kadin et al.\(^2^5\) reported overexpression of SOC2 and SOC3 in primary cutaneous and BIA-ALCL cases.

**Other**

A recent comprehensive genetic analysis of 29 patients found that Genome-wide chromosomal copy number aberrations (CNAs) were detected in 94% of BIA-ALCLs, with losses at chromosome
20q13.13 in 66% of the samples supporting previous studies.\textsuperscript{58,61,63,64} Loss of 20q13.13 was reported to be characteristic of BIA-ALCL compared to other classes of ALCL.

Germline mutations have been recognised in patients with BIA-ALCL including activating mutations of \textit{TP53}\textsuperscript{59,60} as well as mutations of \textit{JAK3}.\textsuperscript{54} TP53 mutations are associated with hereditary cancer syndromes and confer an increased risk to a variety of solid organ malignancies but the relevance of germline mutations as predisposing to this disease requires further exploration. One study involving 13 patients found the human leucocyte antigen allele A*26 to be significantly (\textit{p} < 0.001) less often compared with the general population.\textsuperscript{64} Larger studies are needed to better understand the role of patient genetics in the development of BIA-ALCL.

\textbf{Conclusion}

The etiopathogenesis of BIA-ALCL is likely to be multifactorial, with current evidence-based theories recognising the combination of chronic infection (skewed toward Gram-negative organisms), biofilm formation, implant texturisation, chronic inflammation, host genetics and time in tumorigenesis, providing the preconditions for T-cell malignant transformation. Although silicone bleeds and particles can theoretically provide the antigenic stimulus for chronic inflammation and potential malignant transformation, this premise has yet to be scientifically proven. Additional research is required to establish a unifying theory for the aetiology of BIA-ALCL. Future directions for research should include the identification of specific bacterial antigens or other antigenic stimuli, differential studies of benign and malignant seromas (cytokines, inflammatory, and CD30+ count), and additional genetic sequencing studies in BIA-ALCL cases. Current thinking will continue to evolve as more robust scientific evidence accrues, potentially facilitating better surveillance and treatment.

\textbf{Declaration of Competing Interest}

Prof. Deva is a consultant, research coordinator, educator to Allergan, Mentor (Johnson & Johnson), Sientra, Motiva and Acelity (KCI) He has previously coordinated industry-sponsored research for these companies relating to both biofilms and breast prostheses.

Dr S. Lajevardi, Dr P. Rastogi and Dr D. Isacson have no affiliations or financial interests to disclose.

\textbf{Funding}

None.

\textbf{Ethical approval}

N/A.

\textbf{Supplementary materials}

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jpra.2021.11.006.

\textbf{References}

1. Rastogi P, Riordan E, Moon D, Deva AK. Theories of Etiopathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. \textit{Plast Reconstr Surg}. 2019;143:23s–29s.
2. Barnsley GP, Sigurdson LJ, Barnsley SE. Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: a meta-analysis of randomized controlled trials. \textit{Plast Reconstr Surg}. 2006;117:2182–2190.
3. Wong CH, Samuel M, Tan BK, Song C. Capsular contracture in subglandular breast augmentation with textured versus smooth breast implants: a systematic review. \textit{Plast Reconstr Surg}. 2006;118:1224–1236.
4. Ajdic D, Zoghbi Y, Gerth D, Panthaki ZJ, Thaller S. The relationship of bacterial biofilms and capsular contracture in breast implants. \textit{Aesthet Surg J}. 2016;36:297–309.
5. den Braber ET, de Ruijter JE, Smits HT, et al. Effect of parallel surface microgrooves and surface energy on cell growth. \textit{J Biomed Mater Res}. 1995;29:511–518.
6. Henderson PW, Nash D, Laskowski M, Grant RT. Objective Comparison of Commercially Available Breast Implant Devices. Aesthetic Plast Surg. 2015;39:724–732.

7. Sforza M, Zaccheddu R, Alleruzzo A, et al. Preliminary 3-Year Evaluation of Experience With SilkSurface and VelvetSurface Motiva Silicone Breast Centers: Experience With 5813 Consecutive Breast Augmentation Cases. Aesthet Surg J. 2018;38:562–573.

8. Hu H, Jacombs A, Vickery K, et al. Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: implications for breast implant-associated lymphoma. Plast Reconstr Surg. 2015;135:319–329.

9. Hu H, Johani K, Almatroudi A, et al. Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Plast Reconstr Surg. 2017;136:1659–1669.

10. Shahriari N, Ferenczi K, Heald PW. Breast implant-associated anaplastic large cell lymphoma: a review and assessment of cutaneous manifestations. Int J Womens Dermatol. 2017;3:140–144.

11. Talwalkar SS, Miranda RN, Valbuena JR, et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008;32:1299–1309.

12. Blombery M, Prince HM, Seymour JF. Primary Breast Lymphoma—Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma. J Natl Cancer Inst. 2017;109.

13. Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126:17–25.

14. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–5504.

15. Clemens MW, Medeiros LJ, Butler CE, et al. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016;34:160–168.

16. Pennock ND, White JT, Cross EW, et al. T-cell responses: naive to memory and everything in between. Adv Physiol Educ. 2013;37:273–283.

17. Turner S. An exploration into the origins and pathogenesis of anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-positive Cancers 2017: 9.

18. Malcolm T, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biol. 2016;6.

19. Lowe DB, Storkus WJ. Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy. 2011;3:1265–1274.

20. Burg G, Kempf W, Haeflter A, et al. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res. 2002;160:271–280.

21. Han A, Newell EW, Glanville J, et al. Dietary gluten triggers concomitant activation of CD4+ and CD8+ alpha-beta T cells and gammadelta T cells in celiac disease. Proc Natl Acad Sci U S A. 2013;110:13073–13078.

22. Hardy MY, Tye-Din JA. Coeliac disease: a unique model for investigating broken tolerance in autoimmunity. Clin Transl Immunology. 2016;5:e112.

23. Blombery M, Prince HM, Seymour JF, et al. Survival signals and targets for therapy in breast implant-associated ALK-anaplastic large cell lymphoma. Clin Cancer Res. 2012;18:4549–4559.

24. Sansone P, Bromberg J. Targeting the interleukin-6/jak/stat pathway in human malignancies. J Clin Oncol. 2012;30:1005–1014.

25. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007;117:3846–3856.

26. Kadin ME, Deva A, Xu H, et al. Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2016;36:773–781.

27. Wolfson D, Rabinowitch E, Grundman C, et al. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. Plast Reconstr Surg. 2012;129:337e–337e.

28. Fleury EF, Rego MM, Ramalho LC, et al. Silicone-induced granuloma of breast implant capsule (SIGBIC): similarities and differences with anaplastic large cell lymphoma (ALCL) and their differential diagnosis. Breast Cancer (Dove Med Press). 2017;9:133–140.

29. Mazzocchi M, Dessy LA, Corrias F, Scuderi N. A clinical study of late seroma in breast implantation surgery. Aesthetic Plast Surg. 2012;36:97–104.

30. Ravi-Kumar S, Sanane O, Vasef M, Rabinowitz I, Fekrazad MH. Anaplastic large cell lymphoma associated with breast implants. World J Plast Surg. 2012;1:30–35.

31. Cappellano G, Ploner C, Lobenwein S, et al. Immunophenotypic characterization of human T cells after in vitro exposure to different silicone breast implant surfaces. PLoS ONE. 2018;13:e0192108.

32. Mladick RA. Significance of Staphylococcus epidermidis causing subclinical infection. Plast Reconstr Surg. 2005;115:1426–1427 author reply 27–8.

33. Clinton A, Carter T. Chronic Wound Biofilms: pathogenesis and Potential Therapies. Lab Med. 2015;46:277–284.

34. Loch-Wilkinson A, Beath KJ, Knight RJW, et al. Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-Surface-Area Textured Implants Are Associated with Increased Risk. Plast Reconstr Surg. 2017;140:645–654.

35. Deva AK. Response to "breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): why the search for an infectious etiology may be irrelevant". Aesthetic Surgery Journal. 2017;37:NP122–NP128.

36. Loch-Wilkinson A, Beath KJ, Knight RJW, et al. Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: high-Surface-Area Textured Implants Are Associated with Increased Risk. Plast Reconstr Surg. 2017;140:645–654.

37. Mahjeet AA, Lee W, Mun S, et al. Influence of membrane surface properties on the behavior of initial bacterial adhesion and biofilm development on nonfiltration membranes. Biofouling. 2010;26:313–321.

38. Teughels W, Van Assche N, Slipein I, Quirynen M. Effect of material characteristics and/or surface topography on biofilm development. Clin Oral Implants Res. 2006;17(Suppl 2):68–81.
39. JACOMBS A, TAHIR S, HU H, et al. In vitro and in vivo investigation of the influence of implant surface on the formation of bacterial biofilm in mammary implants. \textit{Plast Reconstr Surg.} 2014;133:471e–480e.

40. RYAN MP, ADLEY CC. \textit{Ralstonia} spp.: emerging global opportunistic pathogens. \textit{Eur J Clin Microbiol Infect Dis.} 2014;33:291–304.

41. PAJKOS A, DEVA AK, VICKERY K, et al. Detection of subclinical infection in significant breast implant capsules. \textit{Plast Reconstr Surg.} 2003;111:1605–1611.

42. RIEGER UM, MESINA J, KALBERMATTE DF, et al. Bacterial biofilms and capsular contracture in patients with breast implants. \textit{Br J Surg.} 2013;100:768–774.

43. SCHREMIL S, HEINE N, EISENMaNN-KLEIN M, PRANTL L. Bacterial colonization is of major relevance for high-grade capsular contracture after augmentation mammaplasty. \textit{Ann Plast Surg.} 2007;59:126–130.

44. VirdEN CP, DobKE MK, STEIN P, PARSONS CL, Frank DH. Subclinical infection of the silicone breast implant surface as a possible cause of capsular contracture. \textit{Aesthetic Plast Surg.} 1992;16:173–179.

45. CALDIERO M, LAROCCA F, JOVENE MR, et al. Microbial Evaluation in Capsular Contracture of Breast Implants. \textit{Plast Reconstr Surg.} 2018;141:23–30.

46. WANG F, MENG W, WANG B, QIAO L. Helicobacter pylori-induced gastric inflammation and gastric cancer. \textit{Cancer Lett.} 2014;345:196–202.

47. WANG MY, LIU XF, GAO XZ. Helicobacter pylori virulence factors in development of gastric carcinoma. \textit{Future Microbiol.} 2015;10:1505–1516.

48. MUNFORD RS. Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant? \textit{Infect Immun.} 2008;76:454–465.

49. JAPPE U. Superantigens and their association with dermatological inflammatory disease: facts and hypotheses. \textit{Acta Derm Venereol.} 2000;20:321–328.

50. IRWIN MJ, HUDSON KR, AMES KT, FRASER JD, GASCOIGNE NR. T-cell receptor beta-chain binding to enterotoxin superantigens. \textit{Immunol Rev.} 1993;131:61–78.

51. KADIN ME, MORGAN J, XI H, GlicksMAN CA. CD30+ T Cells in Late Seroma May Not Be Diagnostic of Breast Implant-Associated Anaplastic Large Cell Lymphoma. \textit{Aesthet Surg J.} 2017;37:771–775.

52. MORRISDEY D, O’SULLIVAN GC, TANGNEY M. Tumour targeting with systemically administered bacteria. \textit{Curr Gene Ther.} 2010;10:3–14.

53. MYCKATYN TM, PARikh RP. Discussion: breast implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: high-Surface-Area Textured Implants Are Associated with Increased Risk. \textit{Plast Reconstr Surg.} 2017;140:655–658.

54. BLOMBERY P, THOMPSON ER, JONES K, et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. \textit{Haematologica.} 2016;101:e387–e390.

55. CRESCENzo R, ABATE F, LASORSa E, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. \textit{Cancer Cell.} 2015;27:516–532.

56. DI Napoli A, Jain P, Duranti E, et al. Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. \textit{Br J Haematol.} 2018;180:741–744.

57. LETOURNEAU A, MAEREVOET M, MİLOWICH D, et al. Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma. \textit{Virchows Arch.} 2018.

58. OSHI N, BRODY GS, KETTERLING RP, et al. Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. \textit{Blood.} 2018.

59. PASTORELLO RG, D’ALMeeIDA COSTA F, OSORIO C, et al. Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. \textit{Diagn Pathol.} 2018;13:10.

60. LEE YS, FileE A, ARTHUR D, FOJO AT, JAFFE ES. Breast implant-associated anaplastic large cell lymphoma in a patient with Li-Fraumeni syndrome. \textit{Histopathology.} 2015;67:925–927.

61. LAURENT C, NICOLAE A, LAURENT C, et al. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. \textit{Blood.} 2020;135:360–370.

62. FLEX E, PETRANGEli V, STELLA L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. \textit{J Exp Med.} 2008;205:751–758.

63. BLOMBERY P, THOMPSON E, RYLAND GL, et al. Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. \textit{Oncotarget.} 2018;9:36126–36136.

64. LOS-de VRIEs GT, DE BOER M, VAN DIJK E, et al. Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma. \textit{Blood.} 2020;136:2927–2932.